(HealthDay) -- All patients with psoriasis should be screened for hepatitis B surface antigen and hepatitis B core antibody prior to the initiation of tumor necrosis factor-alpha inhibitor therapy, according to research published ...
Jul 1, 2012
0
0
(HealthDay)—For patients with moderate to severely active ulcerative colitis (UC), clinical nonresponders to infliximab have high concentrations of infliximab in fecal samples, according to a study published in the August ...
Aug 5, 2015
0
31
A biosimilar of infliximab, CT-P13, has equivalent safety and efficacy to that of the anti-tumor necrosis factor (TNF) monoclonal antibody for treating Crohn's disease in infliximab-naïve patients. Findings from a comparative ...
Dec 11, 2018
0
1
New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), ...
Aug 8, 2012
0
0
Proactive monitoring and dose adjustment of infliximab, a medication commonly used to treat inflammatory bowel disease (IBD), could improve a patient's chances of having a long-term successful response to therapy, a pilot ...
Sep 11, 2014
0
0
(HealthDay)—Treatment with a pricey biological drug was no better than cheaper, conventional therapy in terms of reducing time off from work for people with rheumatoid arthritis, a new study finds.
Jul 1, 2013
0
0
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional ...
Jun 7, 2012
0
0
(HealthDay)—Doctors who treat patients with psoriasis show wide variation in their beliefs about the safety and effectiveness of psoriasis treatments, according to a study published in the February issue of the Journal ...
Feb 7, 2013
0
0
The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2016) showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react ...
Jun 9, 2016
0
1
Treatment with a biological agent was not superior to conventional treatment in terms of the effect on work loss over 21 months in patients with early rheumatoid arthritis (RA) who responded insufficiently to methotrexate, ...
Jul 1, 2013
0
0
